Published in Pipeline

i-Lumen reports new i-SIGHT data on retinal bioelectric stimulation for dry AMD

This is editorially independent content
5 min read

i-Lumen Scientific, Inc. released new clinical findings from its i-SIGHT feasibility study evaluating the use of a non-invasive bioelectric stimulation therapy for the treatment of intermediate-to-advanced dry age-related macular degeneration (AMD).

The results were presented during the 2026 Clinical Trials at the Summit Retina meeting earlier this month.

To start, let’s get familiarized with this therapy.

The i-Lumen AMD System is designed as an investigational, in-office device that delivers a proprietary pulsed microcurrent (bioelectric) stimulation to the retina.

How is this simulation delivered?

Externally and—most importantly—without implants.

The setup: Electrodes are placed on a closed eyelid and the back of the neck to direct the bioelectric stimulation to the retina.

  • Note: This delivery is referred to as transpalpable because the microcurrent passes through the closed eyelid.

Also key to its mechanism: a proprietary software embedded in the device, with preset treatment algorithms, that calibrate to each patient at every session.

Can I get a visual of the process?

Watch below for a visual of how it works.

So what’s the targeted outcome?

i-Lumen essentially describes AMD vision loss as stemming from the dysfunction of retinal pigment epithelium (RPE) and other macular cells. See here and here for more on this.

As such: The company’s therapy is designed to support retinal electrophysiology by boosting transepithelial potential across the RPE and supporting the regenerative processes for healthy photoreceptor cell function.

Alrighty, now to its clinical evaluations.

Two clinical trials to be aware of:

Hold up — isn’t the iSIGHT study already completed?

Indeed it is. After kicking off in 2022, the 12-month feasibility study concluded in June 2025.

And as we previously reported, the only data released to date was 3-month findings.

  • The gist: Over half of treated patients reportedly achieved an improvement in best-corrected visual acuity (BCVA) of ≥2 lines from baseline.

So this latest data readout builds on that initial reporting?

Correct. Sophie J. Bakri, MD, MBA, professor and chair of Ophthalmology at Mayo Clinic, presented the data on behalf of i-Lumen Scientific. The full presentation can be viewed here.

Among the key Month 3 findings:

  • Vision gains: Active-treated study eyes gained a mean of 9.62 Early Treatment Diabetic Retinopathy Scale (ETDRS) letters from baseline.
    • Versus sham: In exploratory analyses, active eyes were 3.9 letters ahead of sham-treated eyes.
    • Versus fellow eyes: were 8.54 letters ahead of untreated fellow eyes

How did photoreceptor response time fare?

As measured by multifocal electroretinography (mfERG), these were associated with improvements in visual acuity (VA).

Speaking of visual acuity …

The new data reported that more than 50% of treated patients achieved a ≥10-letter improvement in best-corrected visual acuity (BCVA) at one or more follow-up visits between Months 2 and 12.

And the retina structure outcomes?

Exploratory optical coherence tomography (OCT) analyses showed improved ellipsoid zone (EZ) integrity during the treatment period.

Notably: This improvement peaked at 47.6% at Week 2, and a 39% improvement was sustained through Month 3.

Now to safety.

Per Dr. Bakri, no unanticipated device-related adverse events (AEs) were reported.

Even further: Overall AE rates were comparable between the active and sham groups.

Let’s talk key takeaways.

Dr. Bakri noted that the data suggests retinal bioelectric stimulation may influence visual function in patients with intermediate-to-advanced dry AMD.And though the study’s design didn’t establish definitive accuracy, “signals observed in visual acuity, retinal electrophysiology, and imaging biomarkers support further evaluation in larger controlled clinical trials,” she stated.

And speaking of further evaluations …

That brings us back to the global iSIGHT2 trial, which is currently enrolling participants across the U.S. and United Kingdom.

Per Clinical Trials, the study’s estimated primary completion is March 2027 followed by a study completion at the end of 2029.